Spots Global Cancer Trial Database for Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors
Official Title: A Multicenter Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of the Combination of Rogaratinib and Copanlisib in Patients With FGFR-positive, Locally Advanced or Metastatic Solid Tumors
Study ID: NCT03517956
Conditions
Study Description
Brief Summary: The primary objective of this study is to determine the safety, tolerability, maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) and efficacy of rogaratinib in combination with copanlisib in patients with locally advanced or metastatic solid tumors that are mRNA-positive for at least one FGFR1-4 subtype. The secondary objectives of this study are to characterize the pharmacokinetics (PK) of rogaratinib and copanlisib alone and in combination, and to assess the anti-tumor efficacy of rogaratinib in combination with copanlisib for locally advanced or metastatic solid tumors that are mRNA-positive for at least one FGFR1-4 subtype.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
USC Norris Hospital and Clinics, Los Angeles, California, United States
Northwestern University, Chicago, Illinois, United States
University of Maryland, Baltimore, Maryland, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Barbara Ann Karmanos Cancer Institute - Detroit, Detroit, Michigan, United States
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Tyler Cancer Center, Tyler, Texas, United States
CU Saint-Luc/UZ St-Luc, Bruxelles - Brussel, , Belgium
UZ Antwerpen, Edegem, , Belgium
CHU de Liège, Liege, , Belgium
Krankenhaus Nordwest, Frankfurt, Hessen, Germany
Universitätsklinikum Köln, Köln, Nordrhein-Westfalen, Germany
Klinikum der Universität Würzburg, Würzburg, , Germany
Severance Hospital, Yonsei University Health System, Seoul, , Korea, Republic of
Asan Medical Center, Seoul, , Korea, Republic of
Samsung Medical Center, Seoul, , Korea, Republic of
National University Hospital, Singapore, , Singapore
National Cancer Center Singapore, Singapore, , Singapore
Ciutat Sanitària i Universitaria de la Vall d'Hebron, Barcelona, , Spain
Hospital Clínico Universitario de Valencia, Valencia, , Spain
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
